Epizyme parts ways with its CEO ahead of big Phase II cancer bet

After more than 5 years in the top spot, Epizyme ($EPZM) CEO Robert Gould is stepping down next month, leaving the company as it presses forward with a pair of promising cancer drugs. Gould will leave the post Sept. 10, maintaining a seat on the board as he is replaced by Robert Bazemore, who served as chief operating officer of Synageva until Alexion Pharmaceuticals ($ALXN) bought it for $8.4 billion last month. Meanwhile, Epizyme is advancing two treatments for blood cancers, hoping to replicate positive Phase I results in mid-stage trials. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.